Recombinant Human NRG1-β1
| Code | Size | Price |
|---|
| LEI-N188-50ug | 50 ug | £580.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Human
Regulatory Status: RUO
Shipping:
Ambient
Storage:
This lyophilized protein is stable for six to twelve months when stored desiccated at -20°C to -70°C. After aseptic reconstitution this protein may be stored at 2°C to 8°C for one month or at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. See Product Insert for exact lot specific storage instructions.
Further Information
Format:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Formulation:
This recombinant protein was lyophilized from a 0.2 um filtered solution in 35% acetonitrile (CH3CN) and 0.1% trifluoroacetic acid (TFA).
Long Description:
Neuregulin/Heregulin is a family of related growth factors that are differentially spliced variants of four genes: NRG1, NRG2, NRG3 and NRG4. The longest forms of NRG contains several different modular domains and tissue-specific splicing results in many NRG isoforms containing different sets of these domains. Alternative splicing produces two types of EGF domain, designated a and b. HRG-Beta1 contains an Ig domain and an EGF domain necessary for direct binding to receptor tyrosine kinases erbB-3 and erbB-4. HRG-Beta1 binding causes erbB-3 and erbB-4 to dimerize with erbB-2 (Her2/neu) and thereby regulates the phosphorylation of erbB-2 tyrosines. HRG-Beta1 stimulates proliferation and motility of breast cancer cells and plays a role in wound healing by stimulating epidermal migration and differentiation of epidermal cells and by stimulating the expression of integrins in the epidermis.
NCBI Gene:
3084
Purity:
>90% by SDS-PAGE and analyzed by silver stain.
Target:
NRG1-beta 1
References
1. Adlkofer, K. and C. Lai (2000) Glia 29:104
Related Products
| Product Name | Product Code | Supplier | Recombinant Human Heregulin-β1 (HRG1-β EGF Domain) | LEI-H1420 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human Neuregulin 1-β1 | LEI-N195 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||